Replimune Group Inc (NASDAQ:REPL) Chairman Sells $490,680.00 in Stock

Replimune Group Inc (NASDAQ:REPL) Chairman Philip Astley-Sparke sold 29,000 shares of the firm’s stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $16.92, for a total value of $490,680.00.

Philip Astley-Sparke also recently made the following trade(s):

  • On Thursday, October 31st, Philip Astley-Sparke sold 14,500 shares of Replimune Group stock. The stock was sold at an average price of $17.02, for a total value of $246,790.00.
  • On Monday, September 23rd, Philip Astley-Sparke sold 14,500 shares of Replimune Group stock. The stock was sold at an average price of $17.05, for a total value of $247,225.00.

NASDAQ REPL opened at $17.15 on Tuesday. The stock has a 50-day simple moving average of $14.61 and a two-hundred day simple moving average of $13.46. The firm has a market capitalization of $538.96 million, a P/E ratio of -12.89 and a beta of 3.30. Replimune Group Inc has a fifty-two week low of $8.88 and a fifty-two week high of $18.25.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings data on Monday, November 11th. The company reported ($0.35) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.34) by ($0.01). Sell-side analysts expect that Replimune Group Inc will post -1.52 earnings per share for the current year.

A number of brokerages recently issued reports on REPL. ValuEngine upgraded Replimune Group from a “sell” rating to a “hold” rating in a research note on Monday, November 4th. Zacks Investment Research lowered Replimune Group from a “buy” rating to a “hold” rating in a research note on Saturday, October 26th. HC Wainwright restated a “buy” rating and issued a $26.00 target price on shares of Replimune Group in a research note on Monday, September 30th. Chardan Capital restated a “buy” rating and issued a $28.00 target price on shares of Replimune Group in a research note on Thursday, October 24th. Finally, Roth Capital raised their target price on Replimune Group from $20.00 to $30.00 and gave the stock a “buy” rating in a research note on Monday. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $25.17.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in REPL. BlackRock Inc. raised its stake in shares of Replimune Group by 8.2% during the 2nd quarter. BlackRock Inc. now owns 1,015,225 shares of the company’s stock valued at $14,883,000 after buying an additional 76,540 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Replimune Group by 7.3% during the 2nd quarter. Vanguard Group Inc. now owns 536,564 shares of the company’s stock valued at $7,866,000 after buying an additional 36,547 shares during the last quarter. Emerald Advisers LLC raised its stake in shares of Replimune Group by 5.2% during the 3rd quarter. Emerald Advisers LLC now owns 728,890 shares of the company’s stock valued at $10,132,000 after buying an additional 35,712 shares during the last quarter. Foresite Capital Management III LLC raised its stake in shares of Replimune Group by 4.0% during the 2nd quarter. Foresite Capital Management III LLC now owns 779,656 shares of the company’s stock valued at $11,430,000 after buying an additional 30,002 shares during the last quarter. Finally, Emerald Mutual Fund Advisers Trust raised its stake in shares of Replimune Group by 3.0% during the 3rd quarter. Emerald Mutual Fund Advisers Trust now owns 733,404 shares of the company’s stock valued at $10,194,000 after buying an additional 21,634 shares during the last quarter. Institutional investors and hedge funds own 60.74% of the company’s stock.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1 that is in Phase I/II clinical trials for a range of solid tumors.

Featured Story: Monthly Dividend Stocks Can Provide Solid Income

Insider Buying and Selling by Quarter for Replimune Group (NASDAQ:REPL)

Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.